← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Aptorum Group Limited (APM) 10-Year Financial Performance & Capital Metrics

APM • • Industrial / General
HealthcareBiotechnologyInfectious DiseasesAntibiotics & Bacterial Infections
AboutAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.Show more
  • Revenue $0 -100.0%
  • EBITDA -$4M +62.6%
  • Net Income -$4M -51.1%
  • EPS (Diluted) -0.78 -25.8%
  • Gross Margin -
  • EBITDA Margin -
  • Operating Margin -
  • Net Margin -
  • ROE -31.43% -29.1%
  • ROIC -18.29% +65.9%
  • Debt/Equity 0.28 +25.7%
  • Interest Coverage -25.84 +70.5%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Trading at only 0.5x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 1/9
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 20.6% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y-
TTM-84.8%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM79.65%

EPS CAGR

10Y-
5Y-
3Y-
TTM82.83%

ROCE

10Y Avg-61.09%
5Y Avg-73.99%
3Y Avg-79.69%
Latest-25.03%

Peer Comparison

Antibiotics & Bacterial Infections
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
PLRZPolyrizon Ltd.16.19M15.5431.08-5.21%
TOVXTheriva Biologics, Inc.7.49M0.21-0.01-388.69%0.08
CTXRCitius Pharmaceuticals, Inc.17.79M0.86-0.14-258.23%-59.6%0.00
ACXPAcurx Pharmaceuticals, Inc.6.32M2.69-0.15-0.25%
ITRMIterum Therapeutics plc17.16M0.32-0.26-69.13%
ANTXAN2 Therapeutics, Inc.34.25M1.25-0.73-56.29%
MCRBSeres Therapeutics, Inc.137.33M15.18-0.8015.37%12.34%6.65
PYPDPolyPid Ltd.73.03M4.39-0.89-10.39%1.25

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+0383.45K535.17K911.51K1.54M1.3M431.38K0
Revenue Growth %--0.4%0.7%0.69%-0.16%-0.67%-1%
Cost of Goods Sold+58.9K318.01K794.54K1.01M1.46M1.22M420.81K255.05K
COGS % of Revenue-0.83%1.48%1.11%0.95%0.94%0.98%-
Gross Profit+-58.9K65.44K-259K-104K81.85K80.06K10.57K-255K
Gross Margin %-0.17%-0.48%-0.11%0.05%0.06%0.02%-
Gross Profit Growth %-2.11%-4.96%0.6%1.79%-0.02%-0.87%-25.13%
Operating Expenses+5.63M10.39M-259K20.17M19.29M17.25M10.61M3.54M
OpEx % of Revenue-27.11%-0.48%22.13%12.51%13.31%24.6%-
Selling, General & Admin2.88M6.73M10.78M7.71M8.03M7.97M4.42M1.47M
SG&A % of Revenue-17.55%20.14%8.46%5.21%6.15%10.23%-
Research & Development2.5M3.1M6.94M11.59M10.87M9.22M5.2M1.94M
R&D % of Revenue-8.09%12.97%12.71%7.05%7.11%12.05%-
Other Operating Expenses257K-9.77M-17.98M877K392K68.95K999K128K
Operating Income+-5.69M-10.33M-18.2M-19.89M-19.21M-17.51M-10.6M-3.8M
Operating Margin %--26.93%-34%-21.83%-12.46%-13.51%-24.57%-
Operating Income Growth %--0.81%-0.76%-0.09%0.03%0.09%0.39%0.64%
EBITDA+-5.63M-9.65M-16.9M-18.56M-18.01M-16.3M-9.48M-3.54M
EBITDA Margin %--25.16%-31.58%-20.36%-11.68%-12.58%-21.97%-
EBITDA Growth %--0.71%-0.75%-0.1%0.03%0.1%0.42%0.63%
D&A (Non-Cash Add-back)58.9K682.29K1.3M1.33M1.19M1.21M1.13M255.05K
EBIT-2.56M-10.68M-16.42M5.16M-27.02M-11.53M-10.6M-4.01M
Net Interest Income+0-4.46M-3.7M-244K-93.6K146.59K-121K-147K
Interest Income44.27K0000146.59K00
Interest Expense04.46M3.7M243.63K93.6K0121.14K146.92K
Other Income/Expense3.13M-4.81M-1.92M0-7.91M5.98M6.26M-361K
Pretax Income+-2.56M-15.13M-20.12M4.92M-27.11M-11.53M-4.34M-4.16M
Pretax Margin %--39.47%-37.59%5.4%-17.58%-8.89%-10.06%-
Income Tax+-14.05K0000000
Effective Tax Rate %0.99%0.98%0.93%1.44%0.92%0.85%0.65%1.03%
Net Income+-2.55M-14.83M-18.69M7.07M-25.05M-9.8M-2.83M-4.27M
Net Margin %--38.68%-34.92%7.75%-16.24%-7.56%-6.55%-
Net Income Growth %--4.82%-0.26%1.38%-4.54%0.61%0.71%-0.51%
Net Income (Continuing)-2.56M-15.13M-20.12M4.92M-27.11M-11.53M-4.34M-4.16M
Discontinued Operations00000000
Minority Interest-14.04K-368.53K-1.51M-3.68M-6.1M-7.88M-9.46M-9.36M
EPS (Diluted)+-0.85-5.31-6.402.00-7.15-2.75-0.62-0.78
EPS Growth %--5.25%-0.21%1.31%-4.58%0.62%0.77%-0.26%
EPS (Basic)-0.85-5.31-6.402.03-7.15-2.75-0.62-0.78
Diluted Shares Outstanding3.01M2.79M2.9M3.15M3.5M3.57M4.52M5.45M
Basic Shares Outstanding3.01M2.79M2.9M3.11M3.5M3.57M4.52M5.45M
Dividend Payout Ratio---0.11%----

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+20.28M28.72M8.03M33.66M12.69M7.07M2.48M959.55K
Cash & Short-Term Investments18.22M13.02M6.25M31.88M8.5M1.99M2.01M874.24K
Cash Only16.25M12.01M5.19M3.5M8.13M1.88M2.01M874.24K
Short-Term Investments1.97M1.01M1.06M28.38M236.62K102.48K00
Accounts Receivable179.49K990.85K487.59K341.06K3.56M1.18M70.94K4.54K
Days Sales Outstanding-943.17332.55136.57842.9332.5360.03-
Inventory1.54M30.64K34.19K39.13K35.77K27.72K00
Days Inventory Outstanding9.52K35.1715.714.078.948.32--
Other Current Assets99.58K14.22M309.03K135.95K71.2K3.34M00
Total Non-Current Assets+11.28M16.35M15.92M10.57M9.22M13.8M18.16M15.17M
Property, Plant & Equipment346.59K4.26M7.09M5.38M4.03M3.17M1.85M0
Fixed Asset Turnover-0.09x0.08x0.17x0.38x0.41x0.23x-
Goodwill00000000
Intangible Assets1.47M1.41M1.31M964.86K880.26K752.71K147.35K0
Long-Term Investments7.39M7.09M7.11M4.08M4.16M9.74M16.1M15.1M
Other Non-Current Assets2.06M119.67K59.83K149.18K149.18K127.3K71.82K71.82K
Total Assets+31.56M45.07M23.95M44.23M21.91M20.87M20.64M16.13M
Asset Turnover-0.01x0.02x0.02x0.07x0.06x0.02x-
Asset Growth %-0.43%-0.47%0.85%-0.5%-0.05%-0.01%-0.22%
Total Current Liabilities+1.33M12.18M2.67M3.87M4.38M12.5M2.1M4.34M
Accounts Payable040.14K000000
Days Payables Outstanding-46.07------
Short-Term Debt480K10.11M0627.92K204.7K6.01M204.41K3.24M
Deferred Revenue (Current)01000K000000
Other Current Liabilities0811.93K55.48K-627.92K-204.7K0-204.41K0
Current Ratio15.24x2.36x3.00x8.70x2.90x0.57x1.18x0.22x
Quick Ratio14.09x2.35x2.99x8.69x2.89x0.56x1.18x0.22x
Cash Conversion Cycle-932.27------
Total Non-Current Liabilities+0143.87K6.43M2.21M23.85K530.78K3.16M14.18K
Long-Term Debt006.33M2.01M0500K3.06M0
Capital Lease Obligations0143.87K97.32K203.04K23.85K30.78K99.48K14.18K
Deferred Tax Liabilities00000000
Other Non-Current Liabilities00000000
Total Liabilities1.33M12.33M9.1M6.08M4.4M13.03M5.26M4.35M
Total Debt+480K10.3M6.47M3.32M217.17K6.85M3.49M3.35M
Net Debt-15.77M-1.71M1.29M-174.98K-7.91M4.97M1.48M2.48M
Debt / Equity0.02x0.31x0.44x0.09x0.01x0.88x0.23x0.28x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage--2.32x-4.92x-81.66x-205.20x--87.51x-25.84x
Total Equity+30.23M32.75M14.85M38.15M17.51M7.83M15.38M11.78M
Equity Growth %-0.08%-0.55%1.57%-0.54%-0.55%0.96%-0.23%
Book Value per Share10.0411.735.1212.105.002.193.402.16
Total Shareholders' Equity30.24M33.11M16.36M41.83M23.61M15.71M24.85M21.13M
Common Stock27.86M28.98M29.04M34.02M35.64M35.71M5355
Retained Earnings-2.55M-17.38M-37.56M-30.49M-55.54M-65.34M-68.16M-72.43M
Treasury Stock00000000
Accumulated OCI-367.78K-1.48M-5.55K53.3K-2.02K33.81K-10.62K89.16K
Minority Interest-14.04K-368.53K-1.51M-3.68M-6.1M-7.88M-9.46M-9.36M

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-5.78M-10.04M-13.38M-15.93M-14.65M-12.32M-7.72M-1.19M
Operating CF Margin %--26.17%-25.01%-17.48%-9.5%-9.51%-17.91%-
Operating CF Growth %--0.74%-0.33%-0.19%0.08%0.16%0.37%0.85%
Net Income-2.55M-15.13M-20.12M4.92M-27.11M-11.53M-4.34M-4.27M
Depreciation & Amortization58.9K682.29K1.3M1.33M1.19M1.21M1.13M255.05K
Stock-Based Compensation001.61M1.48M1.68M1.65M1.27M0
Deferred Taxes00-1.53M-24.46M7.96M000
Other Non-Cash Items-2.93M4.81M4.14M751.03K609.34K-5.05M-6.18M3.03M
Working Capital Changes-195.09K-389.73K1.22M45.55K1.02M1.4M407.07K-211.1K
Change in Receivables-48.01K-2.83K-37.72K-21.68K-16.5K-171.91K417.22K41.35K
Change in Inventory0-30.64K-3.54K-4.95K3.36K8.05K14.52K0
Change in Payables058.55K986.24K800.96K855.27K1.92M398.63K0
Cash from Investing+12.8M-6.06M-108.06K1.84M16.51M2.44M624.77K58.62K
Capital Expenditures-3.06M-6.06M-1.11M-161.31K-137.78K-186.92K-3.02K0
CapEx % of Revenue-15.82%2.07%0.18%0.09%0.14%0.01%-
Acquisitions--------
Investments--------
Other Investing-186.9K83.73K-70.11K1.05M-3.35M2.5M519.18K0
Cash from Financing+9.08M25.48M-7.32M12.42M2.78M6.63M4.09M1.43K
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid000-755.51K0000
Share Repurchases--------
Other Financing0-1.64M040.42K824.24K169.46K-54.53K0
Net Change in Cash--------
Free Cash Flow+-8.84M-16.1M-14.49M-16.09M-14.79M-12.51M-7.73M-1.19M
FCF Margin %--41.99%-27.08%-17.66%-9.59%-9.65%-17.91%-
FCF Growth %--0.82%0.1%-0.11%0.08%0.15%0.38%0.85%
FCF per Share-2.94-5.77-4.99-5.10-4.22-3.50-1.71-0.22
FCF Conversion (FCF/Net Income)2.27x0.68x0.72x-2.25x0.58x1.26x2.73x0.28x
Interest Paid00000000
Taxes Paid00000000

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)-8.43%-47.1%-78.52%26.67%-90.01%-77.35%-24.34%-31.43%
Return on Invested Capital (ROIC)-29.52%-34.05%-57.87%-55.15%-60.57%-117.26%-53.59%-18.29%
Gross Margin-17.07%-48.4%-11.41%5.31%6.18%2.45%-
Net Margin--3868.04%-3491.81%775.31%-1624.38%-756.17%-654.88%-
Debt / Equity0.02x0.31x0.44x0.09x0.01x0.88x0.23x0.28x
Interest Coverage--2.32x-4.92x-81.66x-205.20x--87.51x-25.84x
FCF Conversion2.27x0.68x0.72x-2.25x0.58x1.26x2.73x0.28x
Revenue Growth--39.57%70.32%69.17%-15.95%-66.71%-100%

Frequently Asked Questions

Growth & Financials

Aptorum Group Limited (APM) reported $0.4M in revenue for fiscal year 2024.

Aptorum Group Limited (APM) saw revenue decline by 100.0% over the past year.

Aptorum Group Limited (APM) reported a net loss of $7.1M for fiscal year 2024.

Dividend & Returns

Aptorum Group Limited (APM) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Aptorum Group Limited (APM) had negative free cash flow of $9.0M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.